Table 4.

Association of new onset hypertension with levels of circulating markers of inflammation in 46–49 years old women and men: the Hordaland Health Study.

	Women n = 1155				Men n = 526				Interaction biomarker and sex
Variable	Univariable		Model 2		Univariable		Model 2		Univariable	Model 2
	OR 95% CI	p	OR 95% CI	p	OR 95% CI	p	OR 95% CI	p	p	p
hs-CRPa	1.34 (1.20–1.50)	<0.01	1.18 (1.04–1.34)	<0.01	1.04 (0.91–1.18)	<0.61	0.97 (0.84–1.12)	0.71	<0.01	0.046
hs-CRP
<1 mg/l	Ref		Ref		Ref		Ref		<0.01	0.04
1–<3 mg/l	2.02 (1.41–2.90)	<0.01	1.74 (1.20–2.53)	<0.01	1.40 (0.93–2.14)	0.11	1.22 (0.79–1.90)	0.37
≥3 mg/l	2.91 (1.98–4.29)	<0.01	1.87 (1.20–2.90)	<0.01	1.08 (0.65–1.79)	0.78	0.87 (0.49–1.53)	0.62
Neopterina	1.06 (0.61–1.84)	0.83	1.02 (0.58–1.81)	0.97	0.90 (0.45–1.82)	0.77	0.83 (0.39–1.74)	0.85	0.71	0.69
KTRa	1.92 (0.85–4.32)	0.11	1.11 (0.46–2.67)	0.82	0.90 (0.32–2.49)	0.83	0.71 (0.24–2.09)	0.53	0.25	0.59
PAr indexa	1.34 (0.93–1.93)	0.11	1.31 (0.90–1.90)	0.16	0.99 (0.60–1.63)	0.97	1.00 (0.59–1.68)	0.99	0.34	0.43

Model 2 is adjusted for body mass index, creatinine, physical activity, daily smoking, diabetes, and non-fasting serum triglycerides. For this analysis participants with hypertension at baseline were excluded.Hypertension BP ≥ 130/80 mmHg or use of antihypertensive medication, OR odds ratio, CI confidence interval, hs-CRP high-sensitive C-reactive protein, PAr index ratio: 4-pyridoxic acid/(pyridoxal 5’-phosphate + pyridoxal), KTR kynurenin:tryptophan ratio.

^aOR per 1 unit increase on log-transformed scale for each inflammation marker.

Significant associations are printed in bold.